The use of exenatide in severely burned pediatric patients.

Mecott GA, Herndon DN, Kulp GA, Brooks NC, Al-Mousawi AM, Kraft R, Rivero HG, Williams FN, Branski LK, Jeschke MG

Critical care (London, England)11 Aug 2010Cited by 37 (Europe PMC)

PMID20701787PMCIDPMC2945137DOI10.1186/cc9222PepBankPUB-20701787

Summary

IntroductionIntensive insulin treatment (IIT) has been shown to improve outcomes post-burn in severely burnt patients. However, it increases the incidence of hypoglycemia and is associated with risks and complications. We hypothesized that exenatide would decrease plasma glucose levels post-burn to levels similar to those achieved with IIT, and reduce the amount of exogenous insulin administered.MethodsThis open-label study included 24 severely burned pediatric patients. Six were randomized to receive exenatide, and 18 received IIT during acute hospitalization (block randomization). Exenatide and insulin were administered to maintain glucose levels between 80 and 140 mg/dl. We determined 6 AM, daily average, maximum and minimum glucose levels. Variability was determined using mean amplitude of glucose excursions (MAGE) and percentage of coefficient of variability. The amount of administered insulin was compared in both groups.ResultsGlucose values and variability were similar in both groups: Daily average was 130 ± 28 mg/dl in the intervention group and 138 ± 25 mg/dl in the control group (P = 0.31), MAGE 41 ± 6 vs. 45 ± 12 (respectively). However, administered insulin was significantly lower in the exenatide group than in the IIT group: 22 ± 14 IU patients/day in the intervention group and 76 ± 11 IU patients/day in the control group (P = 0.01). The incidence rate of hypoglycemia was similar in both groups (0.38 events/patient-month).ConclusionsPatients receiving exenatide received significantly lower amounts of exogenous insulin to control plasma glucose levels. Exenatide was well tolerated and potentially represents a novel agent to attenuate hyperglycemia in the critical care setting.Trial registrationNCT00673309.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In severely burned children, daily average glucose was similar with exenatide and intensive insulin treatment.
In plain wordsIn severely burned children, average daily blood glucose was similar with exenatide and intensive insulin treatment.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeDaily average glucose
Study
n = 24
Comparator
Intensive insulin treatment
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
Daily average glucose
130 mg/dl
exenatide
Daily average glucose
138 mg/dl
intensive insulin treatment
Source sentences
Summary
Glucose values and variability were similar in both groups: Daily average was 130 ± 28 mg/dl in the intervention group and 138 ± 25 mg/dl in the control group (P = 0.31), MAGE 41 ± 6 vs. 45 ± 12 (respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
This open-label study included 24 severely burned pediatric patients. Six were randomized to receive exenatide, and 18 received IIT during acute hospitalization (block randomization). Exenatide and insulin were administered to maintain glucose levels between 80 and 140 mg/dl.
Show in the study text Report a problemFND-2070178701
02HumanRandomized controlled trialEfficacy outcome
In severely burned children, glucose variability was similar with exenatide and intensive insulin treatment.
In plain wordsIn severely burned children, blood glucose variability was similar with exenatide and intensive insulin treatment.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeGlucose variability
Study
n = 24
Comparator
Intensive insulin treatment
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
MAGE
41
exenatide
MAGE
45
intensive insulin treatment
Source sentences
Summary
Glucose values and variability were similar in both groups: Daily average was 130 ± 28 mg/dl in the intervention group and 138 ± 25 mg/dl in the control group (P = 0.31), MAGE 41 ± 6 vs. 45 ± 12 (respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
This open-label study included 24 severely burned pediatric patients. Six were randomized to receive exenatide, and 18 received IIT during acute hospitalization (block randomization). Exenatide and insulin were administered to maintain glucose levels between 80 and 140 mg/dl.
Show in the study text Report a problemFND-2070178702
03HumanRandomized controlled trialEfficacy outcome
In severely burned children, exenatide reduced administered insulin versus intensive insulin treatment.
In plain wordsIn severely burned children, exenatide reduced insulin requirements compared with intensive insulin treatment.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseAdministered insulin
Study
n = 24
Comparator
Intensive insulin treatment
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
Administered insulin
22 IU patients/day
exenatide
Administered insulin
76 IU patients/day
intensive insulin treatment
Source sentences
Summary
However, administered insulin was significantly lower in the exenatide group than in the IIT group: 22 ± 14 IU patients/day in the intervention group and 76 ± 11 IU patients/day in the control group (P = 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
This open-label study included 24 severely burned pediatric patients. Six were randomized to receive exenatide, and 18 received IIT during acute hospitalization (block randomization). Exenatide and insulin were administered to maintain glucose levels between 80 and 140 mg/dl.
Show in the study text Report a problemFND-2070178703
04HumanRandomized controlled trialSafety outcome
In severely burned children, hypoglycemia incidence was similar with exenatide and intensive insulin treatment.
In plain wordsIn severely burned children, low blood glucose occurred at similar rates with exenatide and intensive insulin treatment.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeHypoglycemia incidence
Study
n = 24
Comparator
Intensive insulin treatment
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated
Measurements
Hypoglycemia incidence
0.38 events/patient-month
both groups
Source sentences
Summary
The incidence rate of hypoglycemia was similar in both groups (0.38 events/patient-month).
1 context sentence(design, population, supporting numbers)
Summary · context
This open-label study included 24 severely burned pediatric patients. Six were randomized to receive exenatide, and 18 received IIT during acute hospitalization (block randomization). Exenatide and insulin were administered to maintain glucose levels between 80 and 140 mg/dl.
Show in the study text Report a problemFND-2070178704

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 stopped early · source ClinicalTrials.gov (opens in a new tab)

WithdrawnPhase 1/2NCT01573806

Pharmacology of Exenatide in Pediatric Sepsis

Seattle Children's Hospitaln = 0Oct 2012 to est. Oct 2014

Septic Shock · Inflammation · Glucose Homeostasis · Organ Dysfunction · Health-related Quality of Life

Trial page ClinicalTrials.govUpdated 5 Oct 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.